sleep architecture, episodes of hypoxia, sympathetic activation, daytime drowsiness, and have been associated with systemic hypertension, pulmonary hypertension, supraventricular and ventricular arrhythmias, left ventricular remodeling, and adverse cardiovascular events. There is a significant degree of overlap between the two types of sleep apnea. Both forms of sleep apnea are diagnosed by the detection of episodes of apnea or hypopnea (AHI) on a sleep study. Detection of C15 episodes of apnea or hypopnea per hour during sleep study is used as a threshold for the diagnosis of sleep apnea. When C 50% of the episodes of AHI are central in origin, this is arbitrarily classified as CSA. The prevalence of CSA has been estimated to be in over one-third of patients with CHF. Both forms of sleep apnea have attracted a lot of investigative and therapeutic interest. Continuous positive airways pressure-assisted ventilation (CPAP) is the most common form of respiratory assistance used in patients with OSA, whereas adaptive servo ventilation (ASV) is the most commonly used ventilatory assistance in patients with CSA. 1, 3, 7 The later is an algorithm driven close loop ventilator system designed to maintain normal breathing pattern in patients with CSA. Different manufactures use different algorithms in their adaptive ventilator devices, but they all achieve the same goal of maintaining a normal breathing pattern in patients with CSA.
Several smaller studies have shown beneficial effects of ASV in subjective parameters of reduced daytime drowsiness and uninterrupted sleep in patients with CHF and CSA. 1, 3, 4, 11 In addition, several parameters of cardiac performance as well as neuroendocrine abnormalities associated with CHF have also shown an improvement with the use of these ventilatory devices. 2, 4 This has resulted in an increasing use of these ventilator systems in patients with CHF and CSA.
In order to determine the definitive role of ASV in patients with CHF and CSA, a large multicenter randomized study (SERVO-HF study) has recently been conducted and published.
12 SERVO-HF study included NYHA II-IV CHF patients with LVEF B 45%, and, AHI [ 15/hour with C 50% being central events and central AHI C 10/hour. The study randomized 1325 patients to treatment with ASV during sleep or no assisted ventilation (control group). The primary endpoint was the time to the onset of an adverse event (composite endpoints of: all-cause mortality, heart transplant, worsening CHF requiring implantation of a ventricular assist device, appropriate shock(s) in patients with an internal cardiac defibrillator (ICD), and unplanned hospitalization for worsening CHF). No significant difference was observed between the ASVtreated and the control group on the primary endpoint, despite a remarkable reduction of AHI and a subjective improvement in the ASV group. Unexpectedly, a higher cardiovascular mortality was observed in the ASV group compared to the control group (10% vs 7.5%), corresponding to a 33% increase in the relative risk of cardiovascular mortality in the ASV group. Most of the excess mortality was due to sudden deaths. This risk remained constant over time and was independent of the symptomatic improvement experienced by the patients in the ASV group. These results defied the expectation of an improvement in adverse cardiac events with the use of ASV in patients with CSA. The exact reason for increased cardiac mortality with the use of ASV in patients with CHF and CSA, despite a significant reduction in AHI and a subjective improvement, is not clear at this point. This is the subject for intense debate, further sub-analyses, new speculations regarding the mechanism of CSA and more research studies. 6, [12] [13] [14] [15] [16] Based upon the findings of this study, safety warnings and advisories against the use of ASV in patients with CHF and CSA have been issued by several professional societies in the USA, and in several European countries.
14,15 Similar safety warnings have also been issued by the manufacturers of the ASV devices. 15 Despite differences in the algorithms used by different manufactures, there is an agreement about not using any ASV in patients with systolic HF (NYHA II-IV) with LVEF B 45% with mainly CSA (central events C 50% of AHI).
In this issue of the Journal, Tokuda and colleagues have published a study of nine patients with CHF (NYHA class II and III, and sleep apnea, who were treated with ASV for 6 months). 17 They studied the left ventricular function by echocardiography, cardiac adrenergic neuronal function by 123 I-MIBG and 11 C-HED imaging, plasma BNP concentration, urinary and plasma catecholamines at baseline and after 6 months of therapy with ASV. ASV therapy significantly improved AHI and also improved BNP levels. On imaging studies, there was a small and statistically insignificant improvement in the left ventricular ejection fraction (36% ± 5% to 39% ± 5%, P = ns). Heart-tomediastinal ratio on early 123 I-MIBG imaging improved from 2.19 ± 0.58 to 2.40 ± 0.67 (P = 0.045); there was no change in this ratio on delayed imaging, neither was any change in myocardial 123 I-MIBG washout rate across 15 minute and 4 hour imaging. On 11 C-HED cardiac PET imaging, an improvement in myocardial tracer retention at 30 to 40 minute imaging was observed 0.068 ± 0.033/s to 0.075 ± 0.034 (P = 0.029). Based upon these results, the authors conclude that ASV might improve presynaptic cardiac sympathetic neurona function in patients with CHF.
Whereas the results of this study are interesting and highlight the potential of novel molecular imaging modalities in addressing complex clinical questions, however, several limitations need to be kept in mind, while drawing any conclusions from this study. The small sample size does remain a significant limitation. The authors aimed to study the changes in cardiac sympathetic function with ASV in patients with CHF and sleep apnea. However, only 6 out of 9 patients met the criteria for sleep apnea. Of these 5 had OSA and only 1 had CSA. The rationale for the use of assisted ventilation in patients with no sleep apnea is unclear. Furthermore, ASV is recommended for CSA, the reason for choosing ASV rather than CPAP in patients with predominantly OSA is not clear? Of several imaging and non-imaging parameters of cardiac sympathetic function studies by the authors, only early heart-to-mediastinal ratio on 123 I-MIBG imaging and 30 to 40 minute 11 C-HED myocardial retention showed a small change, whereas other showed no change. With the recent finding of increased cardiac mortality with the use of ASV in patients with CHF and CSA and a strong advisory against this use, one needs to exercise caution while interpreting these results. Perhaps, the relationship between CHF and sleep disorders is a lot more complex than a simple cause and effect relationship. Treatments directed towards an epiphenomenon of a basic disease process may not modify the natural history of the basic disease process and may even result in harm because of their effect on other biological processes. The field of cardiology learnt it the hard way via several large research studies, while evaluating the role of anti-arrhythmic agents for the treatment arrhythmias in patients with heart disease and, and for the use of inotropic agents in patients with CHF. [18] [19] [20] Perhaps, a better understanding of the nature of relationship between CHF and sleep disorders is required before we can identify targets for therapy to favorably modify the natural history of CHF.
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